Transdermal Estrogen

Phase 2

UUniversity of Washington

Transdermal Estrogen is one of 56 therapeutic programs targeting Prostate Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate AdenocarcinomaNot yet recruiting

Prostate AdenocarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

57 competitors in Prostate Adenocarcinoma

#DrugCompanyPhaseTrials

Lupron

Sun Pharmaceutical Industries, Inc.

Approved

3 2

Erleada

Johnson & Johnson

Approved

3 3

Nubeqa

Bayer

Approved

1 4

Xtandi

Astellas

Approved

1 5

Firmagon

Ferring

Approved

5 6

Casodex

IIstituto Clinico Humanitas

Approved

5 7

Thalomid

Nexavar

Jevtana

Verzenio

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Not yet recruiting

Prostate Adenocarcinoma

NCT07466498

Clinical

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

Estrogen for Quality-of-Life and Immune Modulation in Prostate Cancer (EQUIP)

Not yet recruiting·UUniversity of Washington·Phase 2·NCT07466498·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Transdermal Estrogen. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Transdermal Estrogen. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity of Washington

Transdermal Estrogen

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News